News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Singulex, Inc.’s Assay For Cardiovascular Risk Assessment Highlighted In Two Presentations At American Heart Association 2013 Scientific Sessions



11/19/2013 7:20:32 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, today announced new data highlighting the Company’s ultrasensitive Erenna® Immunoassay System in the detection of cardiac troponin-I (cTnI). Two studies utilized the Erenna System to measure previously undetectable levels of cTnI in order to assess cardiovascular disease risk in rheumatoid arthritis (RA) and heart failure (HF) patients.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES